Theophylline

Generic Name: Theophylline

Brand Names: Elixophyllin, Elixophylline, Pulmophylline, Quibron-T, Theo-24, Theolair, Uniphyl

Drug Type: Small Molecule

Chemical Formula: C_₇H_₈N_₄O_₂

CAS Number: 58-55-9

Unique Ingredient Identifier: 0I55128JYK

Background: A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.

Indication: For the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.

Associated Conditions: Asthma, Bronchitis, Bronchoconstriction, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD), Chronic bronchial inflammation

Associated Therapies: Airway secretion clearance therapy, Bronchodilation

Clinical Trials

Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy

Phase 4

Completed

Conditions: Contrast Induced Nephropathy
Kidney Diseases
Renal Failure
Adverse Effects

First Posted Date: 2007-06-27

Last Posted Date: 2007-06-27

Lead Sponsor: Technical University of Munich

Target Recruit Count: 254

Registration Number: NCT00492518

Locations: 🇩🇪
Klinikum Rechts der Isar; Technical University of Munich, Munich, Germany

Theophylline in Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Conditions: COPD

Interventions: Drug: Theophylline

First Posted Date: 2006-03-07

Last Posted Date: 2017-07-07

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 24

Registration Number: NCT00299858

Locations: 🇨🇦
Ottawa Hospital, General campus, Ottawa, Ontario, Canada

DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2005-11-15

Last Posted Date: 2009-03-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 1600

Registration Number: NCT00252863

Locations: 🇩🇪
Research Site, Zwickau, Germany

Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2005-11-15

Last Posted Date: 2011-01-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 340

Registration Number: NCT00252785

Locations: 🇯🇵
Research Site, Toyama, Japan

Enhancement of in-Vitro GC Function in Patients With COPD

Phase 2

Completed

Conditions: COPD

Interventions: Drug: placebo
Drug: Fluticasone Propionate
Drug: Theophylline

First Posted Date: 2005-10-19

Last Posted Date: 2019-12-04

Lead Sponsor: Imperial College London

Target Recruit Count: 49

Registration Number: NCT00241631

Locations: 🇬🇧
Windsor chest clinic KEVII Hospital, Windsor, Berks, United Kingdom

Differentiation Induction in Acute Myelogenous Leukemia

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: all-trans retinoic acid (ATRA)
Drug: Valproic acid
Drug: Theophyllin

First Posted Date: 2005-09-15

Last Posted Date: 2015-06-24

Lead Sponsor: University of Bergen

Target Recruit Count: 24

Registration Number: NCT00175812

Locations: 🇳🇴
Haukeland University Hospital, University of Bergen, Bergen, Norway

A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)

Phase 4

Completed

Conditions: Asthma
Allergic Rhinitis

First Posted Date: 2005-09-12

Last Posted Date: 2024-08-15

Lead Sponsor: Organon and Co

Target Recruit Count: 31

Registration Number: NCT00157937

Rosiglitazone Versus Theophylline in Asthmatic Smokers

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: beclomethasone
Drug: inhaled beclomethasone and oral theophylline
Drug: rosiglitazone
Drug: theophylline

First Posted Date: 2005-07-13

Last Posted Date: 2010-01-27

Lead Sponsor: University of Glasgow

Target Recruit Count: 79

Registration Number: NCT00119496

Locations: 🇬🇧
Asthma Research Group, Gartnavel General Hospital, Glasgow, Scotland, United Kingdom

Theophylline in Treating Cancer Patients With Shortness of Breath

Phase 3

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Pulmonary Complications
Quality of Life

First Posted Date: 2004-08-17

Last Posted Date: 2020-04-03

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 3

Registration Number: NCT00003684

Locations: 🇨🇦
Kingston Regional Cancer Centre, Kingston, Ontario, Canada
🇨🇦
Algoma District Medical Group, Sault Sainte Marie, Ontario, Canada
🇨🇦
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada

and more 1 locations

Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-07-22

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00003808

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States

and more 68 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy